Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intranasal DHE shows promise in migraine

Publish date:: June 18, 2020

Key clinical point: Intranasal DHE would provide an alternative to intramuscular and intravenous delivery.

Major finding: 66.3% of patients experienced pain relief within 2 hours.

Study details: Randomized, controlled trial (n = 354).

Disclosures: Dr. Shrewsbury is an employee of Impel Therapeutics, which funded the study. Dr. Charles consults for Amgen, BioHaven, Eli Lilly, Novartis, and Lundbeck.

Citation:

Shrewsbury S et al. AHS 2020. Abstract 832509.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Neurology

HIT-6 may help track meaningful change in chronic migraine,

Vascular dementia risk particularly high in type 2 diabetes,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,

Blood biomarkers could help predict when athletes recover from concussions,

Mortality burden of dementia may be greater than estimated,